Stockscreener 앱 받기
1.62
1.82%
-0.03
시장 영업 전:
1.62
전일 마감가:
$1.65
열려 있는:
$1.65
하루 거래량:
3.53M
Relative Volume:
0.86
시가총액:
$364.06M
수익:
$95,000
순이익/손실:
$-327.27M
주가수익비율:
-0.7642
EPS:
-2.12
순현금흐름:
$-239.25M
1주 성능:
-0.61%
1개월 성능:
-2.99%
6개월 성능:
+57.28%
1년 성능:
+13.29%
1일 변동 폭
$1.56
$1.67
1주일 범위
$1.56
$1.84
52주 변동 폭
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
명칭
Allogene Therapeutics Inc
전화
(650) 457-2700
주소
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.62 | 370.80M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-10-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-05-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | 재개 | Oppenheimer | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-08-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-28 | 재확인 | B. Riley Securities | Buy |
| 2021-10-20 | 개시 | Cowen | Outperform |
| 2021-10-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-10-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | 재개 | Jefferies | Buy |
| 2021-05-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-14 | 개시 | B. Riley Securities | Buy |
| 2021-01-26 | 업그레이드 | Stifel | Hold → Buy |
| 2020-12-10 | 재개 | H.C. Wainwright | Buy |
| 2020-11-24 | 개시 | BofA Securities | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-06-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-19 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2020-05-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-14 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-04-13 | 개시 | SunTrust | Buy |
| 2020-03-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-24 | 개시 | Berenberg | Hold |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-05 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Neutral |
| 2019-05-23 | 개시 | Stifel | Hold |
| 2019-03-29 | 개시 | Piper Jaffray | Overweight |
모두보기
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Bond Watch: Will Allogene Therapeutics Inc stock hit new highs in YEARWeekly Trend Report & Technical Pattern Based Signals - baoquankhu1.vn
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? - Yahoo Finance
Aug Drivers: Will Allogene Therapeutics Inc stock hit new highs in YEAREarnings Risk Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
Allogene Therapeutics Approaches a Defining Period for Its Platform - AD HOC NEWS
Don't Ignore The Insider Selling In Allogene Therapeutics - 富途牛牛
Allogene Therapeutics explores cell therapy trial at ASTCT meeting - Traders Union
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - Yahoo Finance
Allogene EVP Roberts sells $63,189 in stock, gains options By Investing.com - Investing.com Canada
Allogene Therapeutics CEO Chang David D sells $171k in stock - Investing.com Canada
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug - MSN
Allogene Therapeutics SVP sells $13k in stock By Investing.com - Investing.com South Africa
Allogene Therapeutics (NASDAQ:ALLO) EVP Sells $63,189.00 in Stock - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) CEO David Chang Sells 95,269 Shares - MarketBeat
Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) SVP Sells 7,549 Shares of Stock - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) CFO Sells $42,241.76 in Stock - MarketBeat
Allogene Therapeutics (ALLO) Is Up 24.1% After Extended Cash Runway and CAR T Trial Progress - Yahoo Finance
Allogene Therapeutics SVP sells $13k in stock - Investing.com
Allogene Therapeutics SVP sells $40k in stock By Investing.com - Investing.com Canada
Allogene Therapeutics SVP sells $40k in stock - Investing.com
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Allogene Therapeutics Gains Following Positive Ratings and Strategic Plans - StocksToTrade
Allogene Therapeutics’ Strategic Upgrades Signal Strong Market Potential - timothysykes.com
Allogene Therapeutics Sees Potential as Citizens Upgrades to Outperform - StocksToTrade
Setup Watch: Is Allogene Therapeutics Inc attractive at current valuation2025 Investor Takeaways & Daily Profit Maximizing Tips - baoquankhu1.vn
Allogene Therapeutics Gears Up for 2026 as Biotech Positivity Fuels Growth Prospects - StocksToTrade
Record $2.5B Sector Start Spotlights Clinical Oncology Plays - Baystreet.ca
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) EVP Sells 26,269 Shares of Stock - MarketBeat
Take Profit: What are the future prospects of Allogene Therapeutics IncBear Alert & Weekly Momentum Stock Picks - baoquankhu1.vn
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T - ADVFN
Insider Trends: What are the future prospects of Allogene Therapeutics IncTrade Risk Report & Fast Moving Stock Watchlists - baoquankhu1.vn
Decliners Report: Is AMZE part of any ETF2025 Winners & Losers & Safe Entry Zone Tips - baoquankhu1.vn
Earnings Miss: Is Allogene Therapeutics Inc stock a top momentum play - Bộ Nội Vụ
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Sell Signal: What are the risks of holding Allogene Therapeutics Inc2025 Technical Overview & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Earnings Risk: Will Allogene Therapeutics Inc stock hit new highs in YEARJobs Report & Weekly Market Pulse Alerts - baoquankhu1.vn
Allogene Therapeutics Sees Bright Prospects with Upgrades and Awards - StocksToTrade
Allogene Therapeutics Sees Optimistic Outlook as Market Interest Grows - timothysykes.com
Allogene Therapeutics Stock Surges After Promising Market Developments - timothysykes.com
Allogene Therapeutics’ Stock Surges as Analysts Optimistic on Future Outlook - StocksToTrade
Allogene Therapeutics Stock Rises Amid Key Developments - StocksToTrade
Allogene Therapeutics Stock Upgraded as ALPHA3 Trial Inspires Market Confidence - timothysykes.com
Allogene Therapeutics Surges on Positive Analyst Ratings and Arbitration Wins - timothysykes.com
Allogene Therapeutics (ALLO) Upgraded by Citizens to Market Outp - GuruFocus
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Citizens Upgrades Allogene Therapeutics (ALLO) - Nasdaq
Allogene Therapeutics (ALLO) Upgraded to Outperform with Significant Upside - GuruFocus
Allogene upgraded at Citizens on discounted EPS, revenue multiple - Seeking Alpha
CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday - Benzinga
Allogene Therapeutics Inc (ALLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):